VEGF is a homodimer glycoprotein with 45 kDa disulfide bridges involved in angiogenesis, which promotes tumour progression and metastases. VEGF has a variety of effects on vascular endothelium, including the ability to promote vascular endothelium.
VEGF is a homodimer glycoprotein with 45 kDa disulfide bridges involved in angiogenesis, which promotes tumour progression and metastases. VEGF has various effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxia and vascular permeability. VEGF's family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF. The VEGF and its receptor system have proven to be the fundamental regulators of cell signaling of langenogenicity. Most tumours have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine associated with this process. To date, 5 different VEGF isoforms have been described. These isoforms are generated following an alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine kinase flt-1 receptors (VEGFR-1) and flk-1/KDR (VEGFR-2 receptors), which have been expressed almost exclusively on endothelial cells. VEGF and its high affinity binding receptors, tyrosines kinases FLK1 and FLT1, are considered important for the development of embryonic vasculature. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, called sFLT1, which binds vascular endothelial growth factor with high affinity, acting as an inhibitor in angiogenesis. High levels of VEGF are associated with POEMS syndrome, also known as Crow-Fukase syndrome, which affects several organs of the body.
Sensitivity
Sensitivity of dosage: 10 pg/ml.
Measurement range
Dose range: 8.23 to 6.000 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.
Samples
Sample type: Cell Lysates, Serum, Supernatant (cell Lysat volume, 50 μl).
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 17718053 |
| Specifications |
| Accession number | P15692 |
| Dose range | 8.23 to 6.000 pg/ml |
| Sensitivity of the dosage | 10 pg/ml |
| Conjugate | Biotin |
| Product type | ELISA |
| Type of sample | Cellular lysates, Serum, Supernatant |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 7422 |
| Gene symbol(s) | VEGFA analysis |
| Coefficient of inter-dose variation | < 12% |
| Coefficient of intra-dose variation | < 10% |
| Contents of kits | 96-well pre-coated plate, standard, dosing diluent concentrate, biotinylated detection antibody, SAV-HRP, washing pad, chromogen, stop solution, adhesive plate lids |
| Marker or dye | HRP |
| Quantity | 10 x 96 tests |
| Regulatory status | RUO |
| Target | VEGF analysis |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Cell Lysate, 50 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4 h 45 min |
Origin and customs
| Manufacturer ref. | EHVEGFACLX10 |
|---|
| Country of origin | United States |
|---|
| HS customs code | 3002 12 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.